Mazdutide Peptide: Trial Results, China Approval and US Status
Updated 30 October 2026. We rechecked the China approval date (27 June 2025) and added a three-way comparison of mazdutide, retatrutide and tirzepatide built from the published trials. Skip to the trial table.
Mazdutide is further along than most people in this niche realise. It is an approved medicine in China for two indications, it has phase 3 results in the New England Journal of Medicine, JAMA and Nature, and Eli Lilly has finished a phase 2 obesity trial in the United States. It also keeps turning up in FDA warning letters to online peptide sellers.
This page sets out every trial result we could verify, the approval position in China and the US, how it compares with semaglutide, tirzepatide and retatrutide, and the side effect data. For the wider class see weight loss peptides. This is research information only and none of it is medical advice.
Mazdutide Weight Loss Trials at a Glance
Every row below comes from a published paper or an Innovent release we opened while updating this page. Figures are mean percentage change in body weight from baseline, mazdutide against placebo, exactly as each source reports them.
| Trial | Population | Dose | Duration | Mean weight change vs placebo | Source |
|---|---|---|---|---|---|
| GLORY-1, phase 3 | 610 Chinese adults with BMI 28 or more, or 24 to 28 with a weight-related condition | 4 mg weekly | 48 weeks | -11.00% vs +0.30% | NEJM 2025 |
| GLORY-1, phase 3 | Same trial | 6 mg weekly | 48 weeks | -14.01% vs +0.30% | NEJM 2025 |
| GLORY-2, phase 3 | 461 Chinese adults with BMI 30 or more, 16.1% with type 2 diabetes | 9 mg weekly | 60 weeks | -16.65% vs -1.50% (difference 15.15 points) | JAMA 2026 |
| Phase 2, China | 80 Chinese adults with BMI 30 or more, no diabetes | 9 mg weekly | 24 weeks | -12.78% vs +1.80% | Med 2026 |
| Phase 2, USA (Lilly) | 179 US adults with obesity or overweight, no type 2 diabetes | 3 mg (raised to 6 mg after week 32) | 32 weeks (primary endpoint) | -7.3% vs -0.9% | Lancet Diabetes Endocrinol 2026 |
| Phase 2, USA (Lilly) | Same trial | 10 mg weekly | 32 weeks | -15.6% vs -0.9% | Lancet Diabetes Endocrinol 2026 |
| Phase 2, USA (Lilly) | Same trial | 16 mg weekly | 32 weeks | -18.1% vs -0.9% | Lancet Diabetes Endocrinol 2026 |
How to read this table. The GLORY-1 figures are the treatment-policy estimand, which counts everyone regardless of whether they stopped the drug. GLORY-1's primary endpoints were measured at week 32, where the published figures were -10.09% on 4 mg and -12.55% on 6 mg. Innovent's own release also gives an efficacy estimand (people who stayed on treatment) of -12.05% and -14.84% at week 48. An earlier version of this page described 13.38% as a 48-week result; that is Innovent's week 32 efficacy estimand figure for 6 mg, and we have corrected it. The US phase 2 used the efficacy estimand at 32 weeks.
Two cautions before comparing these numbers with anything else. GLORY-1 enrolled people with a mean baseline weight of 87.2 kg and BMI of 31.1, a lighter population than the 9 mg GLORY-2 trial (94.0 kg, BMI 34.3), and the trials ran for different lengths. Percentages from different populations, doses and durations are not directly comparable, which is why the head-to-head data below matter more than any cross-trial ranking.
Not sure which of these you actually need?
Answer five questions about your goal, experience and budget and the Stack Builder shows you a matched research protocol on screen, with the compounds, cycle shape and vendor picks from the vendors we score.
Build your stack, 2 minutesType 2 Diabetes Trials and the Semaglutide Head-to-Head
The diabetes programme is called DREAMS. Two trials supported the September 2025 Chinese approval for glycaemic control, and a third compared mazdutide directly with semaglutide.
| Trial | Population | Doses | Duration | HbA1c change | Weight change | Source |
|---|---|---|---|---|---|---|
| DREAMS-1, phase 3 | 320 Chinese adults with type 2 diabetes on diet and exercise alone | 4 mg and 6 mg vs placebo | 24 weeks | -1.57% and -2.15% vs -0.14% | -5.61% and -7.81% vs -1.26% | Nature 2025 |
| DREAMS-2, phase 3 | 731 Chinese adults with type 2 diabetes on oral drugs | 4 mg and 6 mg vs dulaglutide 1.5 mg | 28 weeks | Fell 0.24 and 0.30 points more than on dulaglutide | Fell 3.78 and 5.76 points more than on dulaglutide | Nature 2025 |
| DREAMS-3, phase 3, open label | 349 Chinese adults with early type 2 diabetes and obesity | 6 mg vs semaglutide 1 mg | 32 weeks | -2.03% vs -1.84% | -10.29% vs -6.00% | Innovent, October 2025 |
DREAMS-3 is the only head-to-head result for mazdutide against semaglutide so far. Its primary endpoint was the share of people reaching both an HbA1c below 7.0% and at least 10% weight loss at week 32: 48.0% on mazdutide against 21.0% on semaglutide, according to Innovent's release. Three things limit it. These are company-reported topline figures, the published design paper confirms it was open label, and semaglutide was tested at 1 mg in people with diabetes. We found no peer-reviewed results paper on PubMed as of 14 October 2026. A second Innovent trial against semaglutide, in overweight or obese adults with fatty liver disease, is listed as active on ClinicalTrials.gov (NCT06884293). For semaglutide itself see the semaglutide side effects guide and semaglutide vs tirzepatide.
What Mazdutide Is
Mazdutide is a once-weekly injectable dual agonist of the GLP-1 receptor and the glucagon receptor. Innovent Biologics develops it in China as IBI362 under an exclusive licence from Eli Lilly, whose code for it is LY3305677, according to Innovent's approval release and Lilly's US trial registration.
The receptor combination is the interesting part. Semaglutide acts on GLP-1 alone. Tirzepatide acts on GIP and GLP-1. Retatrutide acts on GIP, GLP-1 and glucagon. Mazdutide acts on GLP-1 and glucagon, and skips GIP. What the GLP-1 half does on its own is set out in how semaglutide works.
| Compound | GLP-1 | GIP | Glucagon | Source |
|---|---|---|---|---|
| Semaglutide | Yes | No | No | Obesity Reviews 2026 |
| Tirzepatide | Yes | Yes | No | Lilly pipeline |
| Mazdutide | Yes | No | Yes | NEJM 2025 |
| Retatrutide | Yes | Yes | Yes | Lilly pipeline |
A 2026 review in Obesity Reviews explains why glucagon is in the mix: in animal models, glucagon and GLP-1 dual agonists reduce food intake, decrease liver fat and increase energy expenditure, and the GLP-1 side offsets glucagon's tendency to raise blood sugar. The same review is clear that whether dual agonists beat GLP-1 drugs alone "remains to be established in definitive head-to-head studies".
Approval Status: China, the US and Elsewhere
China. Innovent announced on 27 June 2025 that China's National Medical Products Administration had approved mazdutide for chronic weight management in adults with a BMI of 28 or more, or 24 or more with at least one weight-related condition, alongside diet and exercise (Innovent). The brand name is Xinermei, 信尔美 in Chinese (Drugs, Mazdutide: First Approval; Beijing News). A second approval, for glycaemic control in adults with type 2 diabetes, was announced on 19 September 2025 on the strength of DREAMS-1 and DREAMS-2 (Innovent). We could not confirm whether China has approved the 9 mg dose tested in GLORY-2.
United States. Mazdutide is not FDA approved. Lilly's US work so far is phase 1 and phase 2: a completed 48-week phase 2 obesity trial (NCT06124807, published in Lancet Diabetes and Endocrinology in August 2026), a completed phase 2 trial in alcohol use disorder (NCT06817356), and a mazdutide arm in a recruiting phase 2 obesity master protocol (NCT06143956). We found no Lilly-sponsored phase 3 trial of mazdutide on ClinicalTrials.gov, and Lilly's public pipeline page (data as of 5 August 2026) does not list it. There is no announced US filing date, so any date you see quoted elsewhere is a guess.
Elsewhere. We found no approval outside China.
FDA Warning Letters Naming Mazdutide
The FDA has repeatedly named mazdutide in warning letters to online sellers. The letters we checked from Prime Sciences and Summit Research Peptides both quote the sellers' research-only disclaimers and still conclude that the products are unapproved new drugs, because the evidence showed they were intended for human use. Each letter below was issued by the agency's Center for Drug Evaluation and Research.
- NuScience Peptides LLC, Cornelius, North Carolina, 24 August 2026: mazdutide was one of nine products named, alongside survodutide, retatrutide, tirzepatide and semaglutide products.
- Prime Sciences, Scottsdale, Arizona, 31 March 2026: the letter lists Mazdutide (10MG) and quotes the website's weight loss claim for it.
- Xcel Research LLC, 10 December 2024 and Summit Research Peptides, 10 December 2024: both list mazdutide among the GLP-1 class products they sold.
We track these letters as they appear in the peptide enforcement tracker, and the wider legal position of research peptides is in the research peptides legal status guide.
Mazdutide vs Tirzepatide and Retatrutide
The table sets the three drugs side by side using each one's largest published obesity trial that we opened. It is a reading aid, not a ranking: the trials ran for different lengths in different populations and the mazdutide trial enrolled Chinese adults only. Figures are mean percentage change in body weight from baseline.
| Compound | Receptors | Approval | Trial | Dose and duration | Mean weight change vs placebo | Source |
|---|---|---|---|---|---|---|
| Mazdutide | GLP-1, glucagon | China only; not FDA approved | GLORY-2, phase 3, 461 Chinese adults with BMI 30 or more | 9 mg weekly, 60 weeks | -16.65% vs -1.50% | JAMA 2026 |
| Retatrutide | GLP-1, GIP, glucagon | Not approved, still in Lilly's pipeline | Phase 2, 338 adults with obesity | 12 mg weekly, 48 weeks | -24.2% vs -2.1% | NEJM 2023 |
| Tirzepatide | GLP-1, GIP | FDA approved for chronic weight management on 8 November 2023 (Zepbound) | SURMOUNT-1, phase 3, 2,539 adults without diabetes | 15 mg weekly, 72 weeks | -20.9% vs -3.1% | NEJM 2022, FDA |
Mazdutide vs retatrutide. Retatrutide adds GIP on top of GLP-1 and glucagon, and its phase 2 result at 48 weeks (-24.2% on 12 mg) is larger than the 48-week mazdutide result we found (-14.01% on 6 mg in GLORY-1), but the two have never been tested against each other and the retatrutide trial was phase 2. Retatrutide has no approval anywhere that we found, whereas mazdutide is on the market in China. Mazdutide vs tirzepatide. Tirzepatide is the only one of the three with an FDA approval for weight management. Its 72-week phase 3 result is a different trial design from either mazdutide study, so the gap between -20.9% and -16.65% is indicative rather than measured.
Tirzepatide. No trial has compared mazdutide with tirzepatide, and we found none registered on ClinicalTrials.gov. The largest mazdutide figure, 18.1% at 16 mg in Lilly's US phase 2, was measured at 32 weeks in 179 people, so it cannot be ranked against tirzepatide's phase 3 results. For what tirzepatide does in practice see tirzepatide side effects.
Retatrutide. Retatrutide adds GIP on top of the GLP-1 and glucagon combination. In its phase 2 trial it produced a 24.2% mean reduction at 48 weeks on 12 mg, against 2.1% on placebo. Lilly has since reported phase 3 results and lists a planned submission on its pipeline page, but it is not approved, and the FDA named it in the same 2026 warning letters. The two drugs have never been compared head to head, so any gap is indicative rather than measured. See the retatrutide guide, retatrutide side effects and tirzepatide vs retatrutide.
Side Effects
Across the trials the pattern is the familiar one for this class: mostly gastrointestinal, mostly mild to moderate. The detail by trial:
- GLORY-1 (4 mg and 6 mg). Gastrointestinal events were the most common. Adverse events led to stopping treatment in 1.5% on 4 mg, 0.5% on 6 mg and 1.0% on placebo (NEJM). Innovent reported a mean heart rate rise of 2.6 beats per minute in both mazdutide groups at week 48 (Innovent).
- GLORY-2 (9 mg). Vomiting 53.1% vs 1.3% on placebo, nausea 46.9% vs 3.2%, diarrhoea 39.4% vs 6.5%. 2.9% stopped treatment because of adverse events, against none on placebo (JAMA).
- US phase 2 (up to 16 mg). Stopping because of adverse events was most frequent at 16 mg, at 20%, mainly for gastrointestinal reasons (Lancet Diabetes and Endocrinology).
Heart rate is the parameter to watch with any glucagon-containing drug. A 2026 review in the Journal of the American Heart Association found that mazdutide and survodutide raised heart rate to a similar extent as GLP-1 drugs alone, while noting that at least one other dual agonist was discontinued partly over larger heart rate increases. The higher doses also came with more people stopping treatment, which is worth knowing given how often the 9 mg and 16 mg weight loss numbers get quoted on their own.
The Sourcing Problem
The regulatory position is unusual and it is the most important practical fact on this page. Mazdutide is an approved prescription medicine in China and nowhere else we could find. Outside China there is no approved product, and the FDA letters above show the agency treats research-labelled mazdutide sold online as an unapproved drug.
That has a specific consequence for research buyers. With tirzepatide or semaglutide there is at least an approved reference product to compare a vial against. With mazdutide there is very little of that, the compound is unfamiliar enough that few buyers know what to check, and the vendor base carrying it is small. A lot-specific certificate of analysis with the assay method stated is the only signal available, and it matters more here than usual. Anything described here is for research use only, not for human use.
PSPeptides is the vendor in our scorecard that carries mazdutide, and it is the only one we track that ships outside the United States. We have not published a verified price per milligram for this compound, so check the live listing rather than any figure quoted elsewhere. Our scoring across every vendor is in the vendor scorecard, and reconstitution arithmetic is in the reconstitution calculator with syringe reading in how to read an insulin syringe.
Who This Is Actually Relevant To
Honestly, for most readers the answer is nobody yet. Outside China there is no approved product and no announced US filing. If you want the compound with the strongest approved evidence in the US, that is tirzepatide or semaglutide. Mazdutide's distinguishing feature is that it is approved somewhere, which matters a great deal if you are in China and very little if you are not.
Where it is genuinely interesting is as a signal about where the class is going. Mazdutide now has phase 3 data in obesity and diabetes, a head-to-head win over semaglutide 1 mg on Innovent's combined endpoint, and a US dose-ranging trial up to 16 mg. The open question, as the Obesity Reviews authors put it, is whether adding glucagon beats GLP-1 drugs alone in definitive head-to-head trials, and that has not been settled.
Key Takeaways
- Mazdutide (IBI362, LY3305677, brand Xinermei in China) is a once-weekly GLP-1 and glucagon dual agonist, developed in China by Innovent under licence from Eli Lilly.
- China approved it for chronic weight management (announced 27 June 2025) and for type 2 diabetes (announced 19 September 2025).
- GLORY-1 showed -11.00% on 4 mg and -14.01% on 6 mg at 48 weeks against +0.30% on placebo. GLORY-2 showed -16.65% on 9 mg at 60 weeks against -1.50%.
- Lilly's US phase 2 reported up to -18.1% on 16 mg at 32 weeks, with 20% stopping that dose because of adverse events.
- DREAMS-3 is the only head-to-head result, against semaglutide 1 mg in type 2 diabetes, and is company-reported so far. There is no trial against tirzepatide or retatrutide.
- It is not FDA approved, we found no Lilly phase 3, and the FDA has named mazdutide in warning letters to online sellers in 2024 and 2026.
See also: survodutide phase 3 results.
Frequently Asked Questions
What is mazdutide?
Mazdutide, coded IBI362 by Innovent Biologics and LY3305677 by Eli Lilly, is a once-weekly injectable dual agonist of the GLP-1 and glucagon receptors. Innovent develops it in China under a licence from Lilly. It is approved in China for chronic weight management and for glycaemic control in type 2 diabetes. It is not approved by the FDA.
Is mazdutide approved in the US?
No. Mazdutide is not FDA approved. Lilly has run phase 1 and phase 2 trials in the United States, including a completed 48-week phase 2 obesity trial, but we found no Lilly-sponsored phase 3 trial on ClinicalTrials.gov and Lilly's public pipeline page does not list it. The FDA has sent warning letters to online sellers of mazdutide, treating it as an unapproved new drug.
What is the brand name of mazdutide?
In China mazdutide is sold by Innovent Biologics as Xinermei. Innovent announced China's approval for chronic weight management on 27 June 2025 and for glycaemic control in adults with type 2 diabetes on 19 September 2025. There is no US brand name because it is not approved in the United States.
How much weight do you lose on mazdutide?
In GLORY-1, Chinese adults with overweight or obesity lost a mean 11.0% of body weight on 4 mg and 14.0% on 6 mg at 48 weeks, against a 0.3% gain on placebo. In GLORY-2, 9 mg produced a mean 16.65% loss at 60 weeks against 1.50% on placebo. A US phase 2 trial reported 15.6% at 10 mg and 18.1% at 16 mg at 32 weeks.
Is mazdutide better than tirzepatide?
Nobody can say yet, because no trial has compared mazdutide with tirzepatide directly and we found none registered on ClinicalTrials.gov. Comparing separate trials is unreliable because the populations, doses and trial lengths differ. The only reported head-to-head result for mazdutide is DREAMS-3 against semaglutide 1 mg in type 2 diabetes with obesity, where Innovent reported 10.29% weight loss against 6.00% at 32 weeks.
What are mazdutide side effects?
The most common side effects in trials were gastrointestinal: nausea, vomiting and diarrhoea, mostly mild to moderate. In GLORY-2 at 9 mg, vomiting affected 53.1% of participants, nausea 46.9% and diarrhoea 39.4%, and 2.9% stopped treatment because of adverse events. In GLORY-1, Innovent reported a mean heart rate rise of 2.6 beats per minute at week 48.
Is mazdutide the same as retatrutide?
No. They are different molecules, both with Lilly development codes. Mazdutide activates the GLP-1 and glucagon receptors, while retatrutide also activates the GIP receptor, which makes it a triple agonist. Mazdutide is approved in China. Retatrutide has reported phase 3 results but is still in Lilly's development pipeline, and neither is FDA approved. They have never been compared head to head.
Sources
- Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight (GLORY-1), Ji et al, N Engl J Med, 2025
- GLORY-1 published in NEJM, Innovent Biologics press release, May 2025
- Treatment With 9-mg Mazdutide in Chinese Adults With Obesity: the GLORY-2 trial, Gao et al, JAMA, 2026
- Mazdutide 9 mg in Chinese adults with BMI 30 or more without diabetes, phase 2, Ji et al, Med, 2026
- Mazdutide in adults with obesity or overweight: US phase 2 trial, Hsia et al, Lancet Diabetes Endocrinol, 2026
- Mazdutide versus placebo in Chinese adults with type 2 diabetes (DREAMS-1), Zhu et al, Nature, 2025
- Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes (DREAMS-2), Guo et al, Nature, 2025
- Mazdutide shows superiority over semaglutide in DREAMS-3, Innovent Biologics press release, October 2025
- Mazdutide versus semaglutide: design and baseline data of DREAMS-3, Luo et al, Contemp Clin Trials, 2026
- Mazdutide approved by China's NMPA for chronic weight management, Innovent Biologics press release, June 2025
- Mazdutide approved by China's NMPA for glycemic control in type 2 diabetes, Innovent Biologics press release, September 2025
- Mazdutide: First Approval, Shirley, Drugs, 2025
- Mazdutide (brand name Xinermei) launch report, Beijing News, July 2025
- Clinical development pipeline, Eli Lilly and Company, data as of August 2026
- NCT06124807: LY3305677 compared with placebo in adults with obesity or overweight, ClinicalTrials.gov
- NCT06817356: mazdutide compared with placebo in alcohol use disorder, ClinicalTrials.gov
- NCT06143956: Lilly obesity master protocol including a LY3305677 arm, ClinicalTrials.gov
- NCT06884293: IBI362 vs semaglutide in overweight or obese adults with MASLD, ClinicalTrials.gov
- Warning letter to NuScience Peptides LLC, FDA, 24 August 2026
- Warning letter to Prime Sciences, FDA, 31 March 2026
- Warning letter to Xcel Research LLC, FDA, 10 December 2024
- Warning letter to Summit Research Peptides, FDA, 10 December 2024
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity, a phase 2 trial, Jastreboff et al, N Engl J Med, 2023
- Dual glucagon and incretin signalling for obesity and MASH, a narrative review, Ard and Almandoz, Obes Rev, 2026
- Cardiovascular effects of glucagon receptor signalling in multiagonists, Kushner and Michos, J Am Heart Assoc, 2026
Not sure which of these you actually need?
Answer five questions about your goal, experience and budget and the Stack Builder shows you a matched research protocol on screen, with the compounds, cycle shape and vendor picks from the vendors we score.
Build your stack, 2 minutes